No Data
No Data
Beijing Beilu Pharmaceutical (300016.SZ): The 'Cangzhou Phase III Active Pharmaceutical Ingredient Production Project' is expected to achieve the scheduled usage status by the end of September 2024.
On July 16, 2024, Beijing Beilu Pharmaceutical (300016.SZ) received a specific research on the "Construction Progress of Cangzhou Phase III Raw Material Production Project." The company responded that the "Cangzhou Phase III Raw Material Production Project" is expected to reach the designated use status by the end of September 2024. According to the company's global strategy, the Cangzhou production base will be built as the company's chemical raw materials production base. Therefore, in the Cangzhou Phase III Raw Material Production Project, the company will increase investment in research and development of chemical raw materials and build corresponding production workshops to further enrich the company's chemical raw materials product categories, enhance product diversity, and further.
Beijing Beilu Pharmaceutical (300016.SZ): Obtained the registration certificate for Gadoteric Acid and Glucosamine Injection.
On July 5, Gelunhui reported that Beijing Beilu Pharmaceutical (300016.SZ) has recently received the "Drug Registration Certificate" for Gadoteric Acid Injection approved and issued by the State Drug Administration. Gadoteric acid injection is a type of intravenous contrast agent used for magnetic resonance imaging (MRI). It was first approved and marketed in France in 1989 and is used for MRI examinations of the following diseases: (1) brain and spinal cord lesions; (2) spinal lesions; and (3) other systemic pathological examinations (including adult vascular imaging, not recommended for full-body use in children under 6 months), which helps provide an evaluation.
Beijing Beilu Pharmaceutical (300016.SZ): Ganetespib Glucamine has obtained the approval notice for the listing application of chemical raw materials.
On July 1st, Gelunhui reported that Beijing Beilu Pharmaceutical (300016.SZ) recently received the approval notice for the marketing application of gadoteric acid gadolinium glucosamine chemical raw materials issued by the National Medical Products Administration. Gadoteric acid gadolinium glucosamine chemical raw materials can be used for the production of gadoteric acid gadolinium glucosamine injection, which is a vein injection contrast agent used for magnetic resonance imaging (MRI). It was first approved for marketing in France in 1989. This product is only used for the diagnosis of diseases and is used for MRI examination of the following diseases: (1) brain and spinal cord lesions; (2) spinal lesions; (3) other systemic.
Hokuriku Pharmaceutical (300016.SZ): The company's products do not involve biosynthesis technology
Gelonghui May 10 丨 Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that the company's products did not involve biosynthesis technology.
Hokuriku Pharmaceutical (300016.SZ): Jiuwei Zhenxin granules are the first pure traditional Chinese medicine preparation approved in China to treat generalized anxiety disorder
Gelonghui, April 22丨Hokuriku Pharmaceutical (300016.SZ) said on the investor interactive platform that Jiuwei Zhenxin granules are the first pure Chinese medicine formulation approved in China to treat generalized anxiety disorder. In order to improve patients' medication experience and improve patient compliance, the company is developing new prescriptions containing flavoring agents. The new flavor Jiuwei Zhenxin granules will be marketed and sold after approval by the corresponding drug regulatory authorities to better meet the medication needs of patients.
Hokuriku Pharmaceutical (300016.SZ) announced its 2023 annual results, changing profit to loss to 71.7571 million yuan
Hokuriku Pharmaceutical (300016.SZ) released its 2023 annual report. The company's revenue was 891 million yuan...
No Data